BIO-TECHNE (NASDAQ:TECH) and MeiraGTx (NASDAQ:MGTX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.
This table compares BIO-TECHNE and MeiraGTx’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
93.4% of BIO-TECHNE shares are held by institutional investors. Comparatively, 22.7% of MeiraGTx shares are held by institutional investors. 3.8% of BIO-TECHNE shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This is a summary of recent recommendations and price targets for BIO-TECHNE and MeiraGTx, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
BIO-TECHNE presently has a consensus price target of $185.00, indicating a potential upside of 5.30%. MeiraGTx has a consensus price target of $23.67, indicating a potential upside of 92.88%. Given MeiraGTx’s stronger consensus rating and higher possible upside, analysts clearly believe MeiraGTx is more favorable than BIO-TECHNE.
Valuation & Earnings
This table compares BIO-TECHNE and MeiraGTx’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|BIO-TECHNE||$642.99 million||10.32||$126.15 million||$4.07||43.17|
BIO-TECHNE has higher revenue and earnings than MeiraGTx.
BIO-TECHNE pays an annual dividend of $1.28 per share and has a dividend yield of 0.7%. MeiraGTx does not pay a dividend. BIO-TECHNE pays out 31.4% of its earnings in the form of a dividend.
BIO-TECHNE beats MeiraGTx on 9 of the 12 factors compared between the two stocks.
BIO-TECHNE Company Profile
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents. It also provides various products, which serves as predictive biomarkers and therapeutic targets for various human diseases and conditions, such as cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. The Protein Platforms segment offers Biologics tools for researchers to interrogate protein purity and identify contaminants during the development and production of biologics; Western blot, an assay for protein analysis and identification; SimplePlex platform, an enzyme-linked immunosorbent assay for use in research and clinical diagnostics; and Single Cell Western platform to elucidate the properties of individual cells to understand cell behavior. The Diagnostics segment provides blood chemistry and gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market. Bio-Techne Corporation has a strategic cooperation agreement with Micropoint Bioscience. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
MeiraGTx Company Profile
MeiraGTx Holdings plc, an integrated clinical stage gene therapy company, develops various gene therapy products for the lives of patients suffering from acquired and inherited disorders. The company focuses on various areas of unmet medical need comprising inherited retinal diseases, xerostomia, and neurodegenerative diseases. It has four ongoing clinical programs, including AAV-RPE65, which is in Phase I/II clinical trials for the treatment of RPE65-deficiency in adult and pediatric patients; AAV-RPGR that is in Phase I/II clinical trials to treat x-linked retinitis pigmentosa in adult and pediatric patients; AAV-CNGB3 that is in Phase I/II clinical trials for the treatment of achromatopsia in adult and pediatric patients; and AAV-AQP1, which is in Phase I/II clinical trials for the treatment of patients with grade 2 or 3 radiation-induced xerostomia. The company also has a pipeline of preclinical and research programs in other indications. MeiraGTx Holdings plc has a research collaboration and evaluation agreement with Janssen Pharmaceuticals, Inc. the company was founded in 2015 and is based in New York, New York.
Receive News & Ratings for BIO-TECHNE Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BIO-TECHNE and related companies with MarketBeat.com’s FREE daily email newsletter.
- [LLODO] Shooter denied bond in fatal Nebraska fast food restaurant attack
- [LLODO] Ohio police rescue woman trapped in sinking minivan after crashing in river, video shows
- [LLODO] Thanksgiving weather — what to expect
- [LLODO] Philadelphia police seeking suspects from looting spree in wake of Walter Wallace Jr. killing
- [LLODO] North Carolina Democratic governor issues new coronavirus rule: Wear a mask at home if you have guests over
- [LLODO] Tennessee girl, 10, killed by stray bullet while on couch, 3 men arrested
- [LLODO] Seattle City Council approves 18% police budget decrease, reportedly one of biggest cuts nationwide
- [LLODO] An Iowa boy is selling baseball bats from fallen trees to help storm victims
- [LLODO] Scott Peterson among California inmates who received COVID relief funds, prosecutors say